Bank of America Corp DE Has $732,000 Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Bank of America Corp DE lowered its holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 86.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,708 shares of the company's stock after selling 269,630 shares during the period. Bank of America Corp DE's holdings in Centessa Pharmaceuticals were worth $732,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Barclays PLC raised its position in shares of Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after buying an additional 4,952 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth $162,000. Ameriprise Financial Inc. bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth $320,000. XTX Topco Ltd increased its position in shares of Centessa Pharmaceuticals by 122.9% in the fourth quarter. XTX Topco Ltd now owns 22,680 shares of the company's stock worth $380,000 after purchasing an additional 12,506 shares during the period. Finally, Voya Investment Management LLC acquired a new position in Centessa Pharmaceuticals in the fourth quarter valued at about $497,000. Institutional investors and hedge funds own 82.01% of the company's stock.

Analysts Set New Price Targets

CNTA has been the topic of a number of analyst reports. Guggenheim reiterated a "buy" rating and set a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Morgan Stanley restated an "overweight" rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Chardan Capital assumed coverage on Centessa Pharmaceuticals in a research note on Thursday, May 8th. They set a "buy" rating and a $30.00 target price for the company. Wall Street Zen upgraded Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, Needham & Company LLC began coverage on Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They set a "buy" rating and a $35.00 price objective for the company. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Centessa Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $27.89.

Insiders Place Their Bets

In related news, insider Gregory M. Weinhoff sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $12.82, for a total value of $128,200.00. Following the sale, the insider now directly owns 122,279 shares in the company, valued at $1,567,616.78. This represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider David M. Chao sold 7,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $17.17, for a total transaction of $120,190.00. Following the transaction, the insider now owns 225,007 shares of the company's stock, valued at approximately $3,863,370.19. The trade was a 3.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 175,398 shares of company stock valued at $2,551,442 in the last ninety days. 7.09% of the stock is currently owned by insiders.

Centessa Pharmaceuticals Trading Up 0.5%

NASDAQ CNTA opened at $11.92 on Monday. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -7.79 and a beta of 1.48. Centessa Pharmaceuticals plc has a twelve month low of $8.46 and a twelve month high of $19.09. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The business's fifty day moving average is $12.57 and its 200 day moving average is $15.18.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.15. As a group, sell-side analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

Want to see what other hedge funds are holding CNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.